Drug intelligence / Profile preview

Moniatrix

Development stage: Unknown
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Moniatrix is a historical **polyvalent pneumococcal vaccine** reported in a peer-reviewed study of patients with chronic obstructive lung disease. It is intended to induce antibody-mediated immunity against capsular polysaccharide antigens of *Streptococcus pneumoniae*, thereby helping prevent pneumococcal infection and associated disease. The identified publication evaluated serum IgG and IgM responses three years after vaccination; the product's manufacturer, exact serotype valency, formulation, and current marketing status could not be confirmed from the available public-source evidence.

Brand names: Moniatrix

Targets

CPS (Streptococcus pneumoniae capsular polysaccharide)

Beyond the preview

Go deeper on Moniatrix.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Moniatrix.

Explore the full profile